Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362348 · ClinicalTrials.gov registry record · Phase 2
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01362348 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 19 participants.
The verdict
NCT01362348, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.
Interventions
- DRUG pazopanib eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-07-07 |
| Est. Completion | 2012-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01362348
The ClinicalTrials.gov registry entry for NCT01362348 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pazopanib eye drops is the first listed.
NCT01362348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01362348 about?
NCT01362348 is a clinical study titled "12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)". The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.
What is the current status of trial NCT01362348?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2011-07-07. Estimated completion is 2012-04-16.
What interventions are being tested in trial NCT01362348?
The interventions under investigation include: pazopanib eye drops (DRUG).
Who is sponsoring clinical trial NCT01362348?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.